ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cyproterone Acetate

Also written as “Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)”, “Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg” and “Cyproterone acetate”.

Its studies are mostly in Acne Vulgaris · Adenocarcinoma · Hot Flashes, led by 3 companies.

Drug pageCyproterone Acetate: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 25, 20254 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eurofarma Laboratoriosits history only22 open or runningphase 3since Mar 25, 2025Mar 25, 2025Feb 2027phase 3 · NCT06905210
Takedaits history only10 open or runningphase 3since Nov 3, 2009Nov 3, 2009none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since May 2, 2000May 2, 2000none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Teva Pharmaceutical Industries only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 2, 2000First study: phase 3 study in Hot FlashesFirst studyNCT00005623 · United States

TargetBeta

“Androgen Receptor antagonist; Glucocorticoid receptor antagonist; Progesterone receptor agonist”ChEMBL 37, by rule

Studies

The one study Teva Pharmaceutical Industries leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00005623Hot Flashes · United States3Completed

How it is read

Names in the registry

  • “Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)”, 1 entry
  • “Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg”, 1 entry
  • “Cyproterone acetate”, 1 entry
  • “cyproterone acetate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.